Простийпошук |
Розширенийпошук |
Покажчики
|
Професійний пошук |
Рубрикатор НБУВ |
Розподілений пошук |
Бази даних
Наукова періодика України - результати пошуку
Книжкові видання та компакт-дискиЖурнали та продовжувані виданняАвтореферати дисертаційРеферативна база данихНаукова періодика УкраїниТематичний навігаторАвторитетний файл імен осіб
 |
Для швидкої роботи та реалізації всіх функціональних можливостей пошукової системи використовуйте браузер "Mozilla Firefox" |
|
|
Повнотекстовий пошук
| Знайдено в інших БД: | Журнали та продовжувані видання (2) | Реферативна база даних (79) |
Список видань за алфавітом назв: Авторський покажчик Покажчик назв публікацій  |
Пошуковий запит: (<.>A=Chekhun V$<.>) | ||||
|
Загальна кількість знайдених документів : 24 Представлено документи з 1 до 20 |
||||
| ||||
| 1. | 
Chekhun V. F. Tumor cell heterogeneity [Електронний ресурс] / V. F. Chekhun, S. D. Sherban, Z. D. Savtsova // Experimental oncology. - 2013. - Vol. 35, № 3. - С. 154-162. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2013_35_3_3 The paper deals with the analysis of literary data on the tumor cell heterogeneity. Phenotypic, genetic and epigenetic mechanisms of heterogeneity are considered. The heterogeneity or metastasis is considered too. The importance for the biology of populations of tumor cells and the sensitivity of tumors to therapeutic treatment are discussed. | |||
| 2. |
Naleskina L. A. Alteration in lipid composition of plasma membranes of sensitive and resistant Guerin carcinoma cells due to the action of free and liposomal form of cisplatin [Електронний ресурс] / L. A. Naleskina, I. N. Todor, M. M. Nosko, N. Yu. Lukianova, V. M. Pivnyuk, V. F. Chekhun // Experimental oncology. - 2013. - Vol. 35, № 3. - С. 192-197. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2013_35_3_9 Aim - to study in vivo changes of lipid composition of plasma membranes of sensitive and resistant to cisplatin Guerin carcinoma cells under influence of free and liposomal cisplatin forms. The isolation of plasma membranes from parental (sensitive) and resistant to cisplatin Guerin carcinoma cells was by differential ultracentrifugation in sucrose density gradient. Lipids were detected by method of thin-layer chromatography. It was determined, that more effective action of cisplatin liposomal form on resistant cells is associated with essential abnormalities of conformation of plasma membrane due to change of lipid components and architectonics of rafts. It results in the increase of membrane fluidity. Conclusion: reconstructions in lipid composition of plasma membranes of cisplatin-resistant Guerin carcinoma cells provide more intensive delivery of drug into the cells, increase of its concentration and more effective interaction with cellular structural elements. | |||
| 3. | 
Ryabtseva O. D. Individual prognosis of serous ovarian cancer survival patients based on adhesion and proliferation of tumor cells [Електронний ресурс] / O. D. Ryabtseva, S. V. Antipova, N. Y. Lukianova, M. A. Nadirashvili, L. Z. Polishchuk, V. F. Chekhun // Онкология. - 2014. - т. 16, № 1. - С. 28-32. - Режим доступу: http://nbuv.gov.ua/UJRN/OL_2014_16_1_7 Мета роботи - провести імуногістохімічне дослідження експресії маркерів CD44s і Ki-67 у клітинах серозного раку яєчника (РЯ) й оцінити їх клінічне значення. Об'єктом дослідження слугував операційний матеріал 102-х хворих (середній вік <$E59,3~symbol С~3,7> року) на серозний РЯ I - III стадії. Використано клінічні, морфологічний, імуногістохімічний, статистичні методи дослідження. Результати: усі пухлини мали будову серозної аденокарциноми з різною часткою папілярного компонента і солідних структур. Виділено високо-, помірно- і низькодиференційовані форми РЯ і пухлини з низьким і високим ступенем морфологічної злоякісності. Встановлено міжпухлинну гетерогенність РЯ за експресією маркерів Ki-67 і CD44. Кількість пухлин із високою експресією Ki-67 (>> 10 %) і CD44 (>> 10 %) була достовірно більшою у хворих на РЯ низького ступеня диференціювання і високогоіморфологічної злоякісності. Виділено молекулярні фенотипы пухлинних клітин РЯ: CD44<^>+ | |||
| 4. |
Shevchuk O. O. The influence of enterosorption on some haematological and biochemical indices of the normal rats after single injection of melphalan [Електронний ресурс] / O. O. Shevchuk, K. A. Posokhova, A. S. Sidorenko, K. I. Bardakhivska, V. M. Maslenny, L. A. Yushko, V. F. Chekhun, V. G. Nikolaev // Experimental oncology. - 2014. - Vol. 36, № 2. - С. 94-100. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2014_36_2_8 Aim - one of the most prominent side effects of intensive cancer chemotherapy is bone marrow suppression which is an independent negative prognostic factor for the time to tumor progression. The aim of the study was to evaluate the myeloprotective possibilities of carbon enterosorbents in the case of usage of alkilating drug melphalan (L-PAM). L-PAM was injected intravenously to healthy inbred rats to cause the myelosuppression. 3 days before and 7 days after this, suspension of two types of carbon granulated enterosorbents were administered per os one time per day. On 8<^>th | |||
| 5. |
Tkalia I. G. Clinical significance of hormonal receptor status of malignant ovarian tumors [Електронний ресурс] / I. G. Tkalia, L. I. Vorobyova, V. S. Svintsitsky, S. V. Nespryadko, I. V. Goncharuk, N. Y. Lukyanova, V. F. Chekhun // Experimental oncology. - 2014. - Vol. 36, № 2. - С. 125-133. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2014_36_2_14 Objectives: to study hormonal receptor status (HRS) of malignant ovarian tumors (MOT) and determine its clinical significance. Retrospective analysis of case histories of 284 patients with MOT of different genesis of I - IV stages was carried out; immunohistochemical study of paraffin-embedded tissues. The HRS for serous, mucinous ovarian cancer (OC) and sex cord-stromal tumors (SCST) was studied. The phenotype of tumors by HRS in patients with serous OC was determined; overall and relapse-free survival in these patients was evaluated depending on the tumor HRS. Positive expression of ER has been registered in 66,4 % of patients with serous OC, PR - in 63,4 %, TR - in 53,0 %; in patients with mucinous OC - 88,0; 84,0; 60,0 %, respectively. Positive staining of cells of stromacellular tumors has been observed in 74,1 % of patients for ER and 77,8 % - for PR and TR. The highest number of patients with tumor phenotype ER+PR+TR+ has been observed in postmenopause - 52,4 %, especially in late postmenopausal period - 39,0 %. The lowest percentage of patients with mentioned phenotype has been marked in reproductive age - 20,7 %. Most patients of reproductive period had phenotype of tumor ER-PR-TR- (35,1 %), in late postmenopause this phenotype has been observed only in 16,2 %. The patients with serous OC with the positive tumor HRS demonstrated the low indices of overall and relapse-free survival compared to the patients with receptor-negative tumors concerning all steroid hormones (p << 0,05). Conclusions: positive HRS was registered in serous, mucinous OC and in SCST, high percentage of tumors with expression of all receptors of steroid hormones was observed at that. The highest frequency of tumors with positive HRS was recorded in patients with serous OC of late postmenopausal period. The patients with serous OC with receptor-positive tumor phenotype showed the rates of overall and relapse-free survival significantly lower compared to the patients with receptor-negative phenotype of OC. Positive HRS, the same as strong expression of TR in patients with serous OC, is a predictive factor of unfavorable course of tumor process. HRS of MOT can be regarded as the additional criterion for solution of a question concerning application of hormonal therapy as a component of complex treatment for the patients. | |||
| 6. |
Tkalia I. G. Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor [Електронний ресурс] / I. G. Tkalia, L. I. Vorobyova, A. N. Grabovoy, V. S. Svintsitsky, T. O. Tarasova, N. Y. Lukyanova, I. N. Todor, V. F. Chekhun // Experimental oncology. - 2014. - Vol. 36, № 3. - С. 184-190. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2014_36_3_9 Aim - to study anti tumor activity of triptorelin - agonist of gonad otropin-releasing hormone and exemestane - inhibitor of aromatase in monotherapy and in combination with cisplatin on the model of receptor-positive for estrogens and progesterone malignant ascites transplantable ovarian tumor (TOT), to assess therapeutic pathomorphosis and level of VEGF expression in tumor cells using different combinations of cytostatics and hormonal drugs. 72 female Wistar rats, which underwent intraperitoneal transplantation of ascitic TOT, by 5-106 cells per animal, have been involved in the study. Rats were divided into 8 groups, 9 rats in each group. Histological study with assessment of therapeutic pathomorphosis in TOT and immunohistochemical study has been carried out. Survival of animals in the studied groups has been evaluated. Among animals treated in regimen of monotherapy, the most pronounced antiangiogenic activity in TOT has been observed on application of hormonal drugs (triptorelin - 39,4 +- 1,9 and exemestane - 33,9 +- 1,4 %; p = 0,003), the highest grade of treatment pathomorphosis in TOT has been observed at treatment with cisplatin (11,7 %; p = 0,001). Combination of triptorelin and exemestane has amplified antiangiogenic activity in TOT (12,2 +- 0,9 %; p = 0,001), but has not significantly changed rates of pathomorphosis (22,1 +- 0,4 %; p = 0,005) and survival of animals (32,2 %; p = 0,007) as compared with the same rates in rats treated with hormonal drugs in monotherapy. Significant correlation between VEGF expression and pathomorphosis has been established (relative part of viable tumor tissue (RPVTT)) in TOT (r = 0,712; p = 0,001), as well as between RPVTT and life-span of animals (r = -0,320; p = 0,007). However, lack of correlation between VEGF expression in cells of TOT and survival of rats has been determined (r = -0,194; p = 0,11). Combination of cytostatic agent with triptorelin or exemestane has demonstrated significantly high rates of therapeutic pathomorphosis (10,1 +- 0,1 % and 16,2 +- 0,3 %, respectively) and antiangiogenic activity in TOT (21,4 +- 1,4 % and 15,0 +- 1,3 %, respectively) as well as the highest survival of animals (100,0 %, increase of life-span (ILS) = 231,9 % and 85,7 %, ILS = 205,8 %, respectively) as compared with the same one in rats treated in regimen of monotherapy with cisplatin, triptorelin, exemestane or by combination of hormonal drugs. Among animals treated by combination of cytostatic drug with triptorelin, two were cured, and among rats, which received cisplatin and exemestane, one animal was cured. Conclusions% triptorelin and exemestane increase anti tumor activity of cisplatin in respect to the malignant ascitic TOT and significantly increase survival of animals, especially when triptorelin and cisplatin are used in combination. | |||
| 7. |
Chekhun V. F. Peculiarities of antioxidant system and iron metabolism in organism during development of tumor resistance to cisplatin [Електронний ресурс] / V. F. Chekhun, Y. V. Lozovska, A. P. Burlaka, N. Y. Lukyanova, I. N. Todor, L. A. Naleskina // Experimental oncology. - 2014. - Vol. 36, № 3. - С. 196-201. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2014_36_3_11 Aim - to study in vivo the peculiarities of changes of iron metabolism and antioxidant system in dynamics of growth of Guerin carcinoma with different sensitivity to cisplatin. In order to evaluate the content of metallothionein-1 (MT-1) in tumor homogenates and blood serum of rats with cisplatin-sensitive and cisplatin-resistant Guerin carcinoma the immunoenzyme method was used. The evaluation of ceruloplasmin activity, content of "free iron" complexes, superoxide and NO-generating activity of NADPH-oxidase and iNOS activity in neutrophils, blood serum and tumor homogenates was measured by EPR-spectroscopy. Maximal accumulation of MT-1 in blood serum and tumor, more pronounced in resistant strain, at the border of latent and exponential phase of growth has been shown that is the evidence of protective role of this protein in the respect to the generation of free radical compounds. It has been determined that in animals with cisplatin-resistant strain of Guerin carcinoma, increase of "free iron" complexes is more apparent both on the level of tumor and organism on the background on increase of CP/TR ratio that is the consequence of organism antioxidant protection system disorder. Conclutions: mentioned changes in metabolism of iron with its accumulation in tumor and further reprogramming of mitochondria metabolism and activity of NADPH - oxidase for non-transformed cells are favorable conditions for the formation of oxidative phenotype of tumor. | |||
| 8. |
Todor I. N. Metabolic changes during development of Walker-256 carcinosarcoma resistance to doxorubicin [Електронний ресурс] / I. N. Todor, N. Yu. Lukianova, Yu. V. Shvets, Yu. V. Lozovska, V. F. Chekhun // Experimental oncology. - 2015. - Vol. 37, № 1. - С. 19-22. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2015_37_1_5 Aim - to study indices of energy metabolism, content of K<^>+ | |||
| 9. |
Burlaka A. P. Redox-regulation of gelatinases during growth of cisplatin-sensitive and resistant Guerin carcinoma [Електронний ресурс] / A. P. Burlaka, I. I. Ganusevich, Yu. V. Lozovska, N. Yu. Lukianova, V. F. Chekhun // Experimental oncology. - 2015. - Vol. 37, № 1. - С. 36-39. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2015_37_1_8 Study was aimed to analyze the dynamics of changes and study interrelations between content of ferritin, transferrin, active gelatinases (MMP-2 and -9) in blood serum and tumor tissue, free iron, rate of superoxide radicals generation in tumor, activity ofNADPH-oxidase and iNOS in neutrophils rats with sensitive and resistant strains of Guerin carcinoma (GC). In order to obtain resistant tumor, 12 courses of cisplatin chemotherapy have been carried out on rats bearing GC. Levels of transferrin and free iron were determined by analysis of EPR spectra from computerized radiospectrometer EPR RE-1307 at temperature of liquid nitrogen. Rate of superoxide radicals and nitric oxide generation in tumor and neutrophils of blood was determined by EPR using spin traps at room temperature. Content of ferritin in tumor homogenate and blood serum of rats with GC was determined by ELISA method using corresponding kits. Concentration of active forms of MMP-2 and -9 in obtained samples was determined using method of zymography. Unregulated generation of superoxide radicals and NO by mitochondria of tumor cells and NADPH-oxidase and iNOS neutrophils via oxidation of iron-containing proteins causes the accumulation of "free iron" complexes in blood and tumor tissue of rats able to evoke oxide-induced damages of macromolecules. It has been shown that for resistant strain of carcinoma, as compared with sensitive one, significantly higher concentrations of active forms of MMP-2 and -9 in blood serum of rats are typical. Dynamics of gelatinases activity changes in tumor tissue corresponds in general with dynamics of changes in serum. In tumor tissue of rats the indices of gelatinases activity positively correlate with rate of superoxide radicals generation, content of "free iron" complexes, ferritin and activity of transferrin. Cytostatic agent increased levels of reactive oxygen species (ROS) and self-amplify rate of superoxide radicals generation. In turn, activation of MMPs via superoxide-depending regulation allows tumor ceils to facilitate migration, invasion and finally - formation of metastatic centers. Mentioned above tumor "oxide phenotype" determines high level of its aggressiveness and forms corresponding level of drug resistance. Conclusions: Thus, high levels of superoxide radicals oxidize transport proteins and form free iron pool. Iron ions, via Haber - Weiss mechanism, initiate generation of the hydroxyl radicals, which also enhance oxidation processes. | |||
| 10. |
Chekhun V. F. Pharmacological effect of aminoferrocene in mice with L1210 leukemia [Електронний ресурс] / V. F. Chekhun, A. Mokhir, S. Daum, I. N. Todor, N. Yu. Lukianova, Yu. V. Shvets, A. P. Burlaka // Experimental oncology. - 2015. - Vol. 37, № 2. - С. 120-125. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2015_37_2_9 Aim - to study the cytostatic and some biological effects of aminoferrocene using mice with L1210 lymphoid leukemia. Experiments were performed on BDFI male mice (DBA/2, female x C57B1/6, male) with transplantable L1210 lymphoid leukemia. Determination of antitumor activity of Benzyl-Fc Boron (Bn), it was injected intraperitoneally 6 times daily, starting on day 2 after L1210 leukemia cell transplantation. Doses of Bn such as 26; 260 and 2600 mu g/kg were used. The determination of intracellular content of cardiolipin, thiols, reactive oxygen species (ROS) and also analysis of Annexin V positivity and mitochondrial transmembrane potential (JC-1 staining) were performed with use of flow cytometry. The levels of "free iron" complexes, transferrin active forms and the rate of NO generation were measured by EPR-specroscopy. Six daily injections of Bn at a dose of 26 mu g/kg resulted in an increased survival of mice with L1210 leukemia by 28 % (p << 0,05). Bn led to an increase of apoptotic cells number and ROS amount in leukemia cells. Besides, Bn caused a decrease of cardiolipin and nonprotein thiol compounds content. The membrane electrochemical potential of cell mitochondria was decreased also after Bn administration. Studies using EPR-spectroscopy revealed a significant increase in a level of "free iron", content of transferrin active species and generation rate of NO by inducible NO-synthase in L1210 cells after aminoferrocene administration. Conclusion: our data indicate that Benzyl-Fc Boron can be promising candidate for realizing a new strategy of anticancer therapy with the use of ROS-inducing agents. | |||
| 11. |
Shevchuk O. O. Prevention of myelosuppression by combined treatment with enterosorbent and granulocyte colony-stimulating factor [Електронний ресурс] / O. O. Shevchuk, K. A. Posokhova, I. N. Todor, N. Yu. Lukianova, V. G. Nikolaev, V. F. Chekhun // Experimental oncology. - 2015. - Vol. 37, № 2. - С. 135-138. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2015_37_2_12 Hema to toxicity and its complication are the prominent limiting factors for rational treatment of malignancies. Granulocyte colonystimulating factor (G-CSF) is used to increase granulocyte production. It has been shown previously that cnterosorption causes prominent myeloprotective activity also. Still, no trial was performed to combine both of them. Aim - to study the influence of combination of enterosorption and pharmaceutical analogue of naturally occurring G-CSF (filgrastim) on bone marrow protection and the growth of grafted tumor in a case of injection of melphalan (Mel). Mel injections were used for promotion of bone marrow suppression in rats. Carbon granulated enterosorfoent C2 (IEFOR) was used for providing of enteral sorption detoxifying therapy. Filgrastim was used to increase white blood cells (WBC) count. The simultaneous usage of enterosorption and filgrastim had maximum effectiveness for restoring of all types of blood cells. WBC count was higher by 138,3 % compared with the Mel group. The increase of platelets count by 98,5 % was also observed. In the group (Mel + C2 + filgrastim) the absolute neutrophils count was twofold higher, in comparison with rats of Mel group. Conclusion: simultaneous administration of G-CSF-analogue and carbonic enterosorbent C2 is a perspective approach for bone marrow protection, when the cytostatic drug melphalan is used. Such combination demonstrates prominent positive impact on restoring of all types of blood cells and had no influence on the antitumor efficacy. | |||
| 12. | 
Chekhun V. F. Metalloproteins during development of Walker-256 carcinosarcoma resistant phenotype [Електронний ресурс] / V. F. Chekhun, Yu. V. Lozovska, A. P. Burlaka, I. I. Ganusevich, Yu. V. Shvets, N. Yu. Lukianova, I. M. Todor, D. V. Demash, A. A. Pavlova, L. A. Naleskina // The Ukrainian Biochemical Journal. - 2015. - Vol. 87, № 2. - С. 103-112. - Режим доступу: http://nbuv.gov.ua/UJRN/BioChem_2015_87_2_11 Проведено дослідження функціонального стану металовмісних протеїнів у сироватці крові (СК) і пухлині щурів у процесі формування резистентного фенотипу злоякісно трансформованих клітин під час проведення 12 курсів хіміотерапії з доксорубіцином. Встановлено, що на всіх етапах формування резистентності до доксорубіцину, в пухлинній тканині тварин із карциносаркомою Уокер-256 відбувається істотне підвищення вмісту протеїнів - трансферину та феритину, що задіяні у транспорті та депонуванні заліза у порівнянні з тваринами, яким доксорубіцин не вводили. У СК цих тварин виявлено зниження рівня феритину на початковому етапі формування резистентності до доксорубіцину та істотне підвищення за сформованого резистентного фенотипу пухлини. Протилежний характер змін виявлено щодо вмісту трансферину. Крім того, у процесі розвитку резистентності до доксорубіцину в пухлинній тканині зростає рівень "вільного заліза", який вірогідно корелює з підвищенням генерації АФК і концентрацією активних форм матриксних металопротеїназ - МП-2 і ММП-9. Поряд із цим поступово збільшується вміст непротеїнових SH-груп у пухлині. У СК на початку формування резистентності відбувається значне зростання активних форм церулоплазміну та різке їх зниження у разі повної втрати пухлиною чутливості до доксорубіцину. Отже, феномен формування резистентності карциносаркоми Уокер-256 супроводжується як дерегуляцією металовмісних протеїнів у СК і пухлинній тканині, так і зміною активності системи антиоксидантного захисту. Таким чином, внаслідок проведеного дослідження окреслено коло металовмісних протеїнів, які задіяні у формуванні резистентного фенотипу пухлин. Вони можуть слугувати мішенню для засобів корекції, що спрямовані на подолання резистентності до доксорубіцину. | |||
| 13. |
Chekhun V. F. Modifying effects of lactoferrin in vitro on molecular phenotype of human breast cancer cells [Електронний ресурс] / V. F. Chekhun, I. V. Zalutskii, L. A. Naleskina, N. Yu. Lukianova, T. M. Yalovenko, T. V. Borikun, S. O. Sobchenko, I. V. Semak, V. S. Lukashevich // Experimental oncology. - 2015. - Vol. 37, № 3. - С. 181-186. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2015_37_3_4 Aim - to assess the role of endogenous lactoferrin (LF) in the formation of the molecular phenotype of human breast cancer (BC) cell lines with varying degrees of malignancy, including cisplatin/doxorubicin resistant cell lines, and identify possible impact of exogenous LF. 5 breast cell lines of different origin - MCF-10 A, MCF-7, including doxorubicin/cisplatin resistant ones, T47D, MDA-IVIB-231, and IV1DA-MB-468. Immunocytochemistry: expression of LF, Ki-67, adhesion molecules E- and N-cadherin, CD44, CD24 rating the invasive potential of cells. Expression of LF in human BC cell lines varies. It is associated with the heterogeneity of molecular profiles of cell lines in terms of adhesion. A link has been established between the level of LF expression in the resistant cell line MCF-7/CP and MCF-7/Dox, features of their molecular profile and invasive properties. Exogenous LF was shown to be capable of modify ing the molecular profile and invasive properties of all the studied cell lines including resistant ones (1WCF-7/CP and MCF-7/Dox). Conclusions: the sensitivity of cytostatic-resistant cell lines (MCF-7/CP and MCF-7/Dox) tends to increase under the influence of exogenous LF. It is likely that this effect is due to LF-mediated inhibition of the expression of proteins associated with drug resistance. | |||
| 14. | 
Gorobets O. Fractal Dimension of the Resistant and Sensitive to Doxorubicin Breast Cancer Cells, Exposed in the Magnetic Field [Електронний ресурс] / O. Gorobets, S. Gorobets, V. Chekhun, O. Medviediev, O. Berezin, O. Garkavenko // Proсeedings of the National Aviation University. - 2015. - № 4. - С. 67-71. - Режим доступу: http://nbuv.gov.ua/UJRN/Vnau_2015_4_12 Досліджено фрактальну розмірність резистентних та чутливих до дії доксорубіцину клітин раку молочної залози, експонованих у магнітному полі. Виявлено, що резистентні та чутливі до дії доксорубіцину клітини раку молочної залози лінії MCF мають різне значення фрактальної розмірності. Мета роботи - перевірка можливості використання фрактальної розмірності як маркеру для визначення чутливості до дії доксорубіцину клітин раку молочної залози лінії MCF, експонованих у магнітному полі. | |||
| 15. |
Chekhun V. F. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics [Електронний ресурс] / V. F. Chekhun, T. V. Borikun, N. Y. Lukianova // Experimental oncology. - 2016. - Vol. 38, № 1. - С. 26-30. - Режим доступу: http://nbuv.gov.ua/UJRN/EOL_2016_38_1_6 Aim - to analyze expression of miRNA in human breast cancer cells, sensitive and resistant to cisplatin and doxorubicin, and to explore possible modification of drug sensitivity via treatment of cells with 5-azacvtidine (5-aza), a demethylating agent. The study was performed on wild-type MCF-7 cell line (MCF-7/S) and its two sublines MCF-7/Dox and MCF-7/DDP resistant to doxorubicin and cisplatin, respectively. Cells were treated with 5-aza, cisplatin, doxorubicin and their combinations. Relative expression levels of miRNA-221, -200b, -320a, -10b, -34a, -122 and -29b were examined, using qRT-PCR. The MTT assay was used to monitor cell viability. We compared miRNA expression profiles in MCF-7/S and drug resistant MCF-7/Dox and MCF-7/DDP cells. Changes of miRNA-221, -200b, -320a, -10b, -34a, -122 and -29b were observed in both resistant cell lines. The most significant differences were found for miRNA-200b (decreased in 50,0 +- 2,6 and 63,0 +- 3,1 times for MCF-7/Dox and MCF- 7/DDP cells, respectively) and for oncogenic miRNA-221 levels (increase in 62,0 +- 5,7 times for MCF-7/Dox and 83,8 +- 7,2 times for MCF-7/DDP cells). 5-aza treatment caused an increase of miRNA-10b, -122, -200b levels in MCF-7/S cells, miRNA-34a, -10b, -122, -200b and -320a levels in MCF-7/Dox cells and miRNA-34a, -10b, -200b and -320a levels in MCF-7/DDP cells. Pretreatment of all studied lines with 5-aza resulted in the increase of their sensitivity to studied cytostatics. In particular, the IC50 of doxorubicin decreased by 2-, 4- and 3-fold for cell lines MCF-7/S, MCF-7/Dox and MCF-7/DDP cells, respectively, and IC50 of cisplatin in studied cultures decreased by 3-, 2- and 1,5-fold, respectively. Conclusions: it was shown that use of 5-aza can modify sensitivity of breast cancer cells to cytotoxic drugs not only by it's demetylation effect, but also by changes in expression of miRNAs, involved in cell proliferation, migration and drug resistance development. | |||
| 16. |
Chekhun V. F. Remodulating effect of doxorubicin on the state of iron-containing proteins, and redox characteristics of tumor with allowance for its sensitivity to cytostatic agents [Електронний ресурс] / V. F. Chekhun, Yu. V. Lozovska, A. P. Burlaka, I. I. Ganusevich, Yu. V. Shvets, N. Yu. Lukyanova, I. M. Todor, N. A. Tregubova, L. A. Naleskina // The Ukrainian Biochemical Journal. - 2016. - Vol. 88, № 1. - С. 99-108. - Режим доступу: http://nbuv.gov.ua/UJRN/BioChem_2016_88_1_13 Досліджено вміст заліза та залізовмісних протеїнів, а саме феритину та трансферину, в сироватці крові (СК) і пухлинній тканині (ПТ) тварин із чутливою та резистентною до доксорубіцину карциносаркомою Уокер-256 до та після дії цитостатика. Встановлено, що в СК і ПТ обох груп тварин за дії препарату відбувається паралельне зниження вмісту загального заліза, трансферину на тлі одночасного зростання вмісту феритину, що виявляє вираженіший характер у тварин із резистентними пухлинами. Показано, що за дії доксорубіцину в ПТ тварин із різною чутливістю до цитостатика спостерігаються протилежні зміни їх редокс-статусу, зміною вмісту комплексів "вільного" заліза, генерації АФК і концентрації активних форм матриксних металопротеїназ-2 і -9, а саме - зростання їх у тварин з чутливими пухлинами та зниження - з резистентними. Одержані дані можуть слугувати критерієм для розробки програм корекції порушень метаболізму заліза з метою підвищення чутливості пухлин до дії цитостатиків. | |||
| 17. | 
Chekhun V. F. Medical physics: molecular aspects [Електронний ресурс] / V. F. Chekhun, K. A. Chalyy, Y. F. Zabashta, L. Y. Vergun, B. V. Batsak // Ukrainian journal of physics. - 2015. - Vol. 60, № 9. - С. 892-904. - Режим доступу: http://nbuv.gov.ua/UJRN/Ukjourph_2015_60_9_12 | |||
| 18. |
Kozachkova O. M. Complexes of palladium(II) with 1-phenyl-1-hydroxymethylene bisphosphoniс acid and their antitumor activity [Електронний ресурс] / O. M. Kozachkova, N. V. Tsaryk, V. V. Trachevskyi, A. B. Rozhenko, Yu. H. Shermolovich, O. I. Guzyr, N. I. Sharykina, V. F. Chekhun, V. I. Pekhnyo // The Ukrainian Biochemical Journal. - 2017. - Vol. 89, № 2. - С. 106-115. - Режим доступу: http://nbuv.gov.ua/UJRN/BioChem_2017_89_2_12 | |||
| 19. | 
Shevchuk O. O. Efficacy of granulocyte colony-stimulating factor and enterosorption in melphalan-induced bone marrow suppression in guerin carcinoma grafted rats [Електронний ресурс] / O. O. Shevchuk, I. M. Todor, N. Yu. Lukianova, N. K. Rodionova, V. G. Nikolaev, V. F. Chekhun // International journal of medicine and medical research. - 2019. - Vol. 5, Iss. 1. - С. 66-74. - Режим доступу: http://nbuv.gov.ua/UJRN/ijmmr_2019_5_1_12 | |||
| 20. | 
Petranovska A. L. Magnetically sensitive nanocomposites and magnetic liquids based on magnetite, gemcitabine, and antibody HER2 [Електронний ресурс] / A. L. Petranovska, M. V. Abramov, N. M. Opanashchuk, S. P. Turanska, P. P. Gorbyk, N. V. Kusyak, А. P. Kusyak, N. Yu. Lukyanova, V. F. Chekhun // Хімія, фізика та технологія поверхні. - 2019. - Т. 10, № 4. - С. 419-431. - Режим доступу: http://nbuv.gov.ua/UJRN/khphtp_2019_10_4_11 Досліджено процеси адсорбції гемцитабіну (ГЦ) на поверхні нанорозмірного однодоменного магнетиту (Fe | |||
| ||||
Попередній перегляд: 
Реферативна БД
 |
| Відділ наукової організації електронних інформаційних ресурсів |
 Пам`ятка користувача |